T h e successful design of orally active non-toxic selective metal chelators is a much sought-after goal. In order to identify an ideal chelator for clinical use, a range of specifications must be considered, such as metal selectivity and affinity, kinetic stability of the complex, bioavailability and toxicity. In this overview the comparative properties of ligands capable of endowing complexes with such properties will be discussed.
Introduction
Therapeutic chelating agents are generally designed with the view of removing toxic metals, although some find utilization in the enhancement of the bioavailability of essential metals such as iron and zinc. Toxic metals are wide ranging and include redox-active ions such as iron, cobalt and copper, radioactive isotopes such as plutonium and indium, and the so-called heavy metals such as lead and mercury. T h e reader is directed to general reviews relating to the selectivity of different ligand classes for a wide range of toxic metals [ 1-31, in this presentation the principles associated with the design of such molecules will be presented using iron(II1) as an example.
Metal selectivity and affinity
In designing iron chelators for clinical application, the properties for metal selectivity and resultant ligand-metal complex stability are paramount. T h e selection of an appropriate ligand for metal complexation can be rationalized by classification of metals and ligands according to the concept of the ' hard ' and ' soft ' acids and bases principle [4] .
Ligands that contain at least one electron pair to be donated for bond formation are generally considered as Lewis bases and metal cations are regarded as Lewis acids. Hard metal cations retain their non-valence electrons very strongly and as a result are of small size and high charge density.
Such cations tend to form strong complexation with hard ligands which contain highly electronegative donor atoms. Correspondingly, soft metal cations are of low charge density and prefer to associate with soft ligands containing donor atoms, which also possess a low charge density.
In theory, chelating agents can be designed for either the iron(I1) (ferrous) or iron(II1) (ferric) oxidation state. High-spin iron( 111) is a spherically symmetrical tripositive cation of radius 0.65 A, and as such is classified as a hard Lewis acid by virtue of its high charge density. It forms most stable bonds with hard ligands such as charged hydroxamate oxygen atoms. In contrast, the iron( 11) cation, which has relatively low charge density, prefers chelators containing soft donor atoms, exemplified by the nitrogen-containing ligands such as 2,2'-bipyridyl. Ligands that prefer iron(I1) retain an appreciable affinity for other biologically important bivalent metals such as copper ( 11) high-affinity iron( 111) chelators is that, under aerobic conditions, they will chelate iron( 11) cations and autoxidize them to the iron( I I I) species [S] . Thus, high-affinity iron( 111)-selective ligands bind both iron(II1) and iron(I1) under most physiological conditions.
Thermodynamic stability of iron(ll1) complexes
Ligands can be structurally classified according to the number of donor atoms that each molecule possesses for co-ordinate bond formation. Ligands that contain one donor atom, such as NH, and water, are termed monodentate. When a ligand contains two or more donor atoms they are termed bidentate, tridentate, tetradentate, hexadentate or generally multidentate. A factor of great importance in the stability of a metal complex is the number of chelate rings formed in the resultant ligand-metal complex. The more rings the greater the stability of the complex. T h e number of chelating rings can be enhanced by increasing the number of donor atoms attached to the ligand. For example, a metal ion with a co-ordination number of six may form three rings with a bidentate ligand or five rings with a hexadentate ligand. Significantly, the majority of natural siderophores are hexadentate ligands.
Under biological conditions, a comparison standard which is generally more useful than the stability constant is the pFe3+ value. pFe3+ can be defined as the negative logarithm of the concentration of the free iron (II1) 
The influence of lipophilicity and molecular mass
In order for a chelating agent to exert its pharmacological effect, a drug must be able to reach the target sites at a sufficient concentration. Hence the key property for an orally active iron chelator is its ability to be efficiently absorbed from the gastrointestinal tract and cross biological membranes to access the desired target sites such as liver, the major iron storage organ. There are three major factors which influence a compound's ability to freely permeate a lipid membrane, namely lipophilicity, ionization state and molecular size. Lipophilicity is a measure of the affinity of a molecule for a lipophilic environment and is commonly assessed by measuring the distribution ratio of the solute (partition coefficient) between two phases, typically n-octanol and water. In order to achieve efficient oral absorption, the compound should possess appreciable lipid solubility to allow the molecule to penetrate the gastrointestinal tract (partition coefficient > 0.2) [8] . However, highly lipid-soluble molecules (partition coefficient > 1.0) can also penetrate most cells and critical barriers, such as the bloodbrain and placental barriers, thereby possessing an increased potential to cause toxicity. Orally active iron(ll1) ligands
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Molecular mass is another critical factor which influences the rate of oral drug absorption. Non-facilitated diffusion is generally considered to be dominant for drugs with molecular masses < 200 Da. T h e 'cut-off' molecular mass for absorption by the human small intestine is approx.
500 Da [9] . In order to achieve greater than 70 oral absorption, the molecular mass of a chelator probably needs to be less than 300 Da. This molecular-mass limit provides a considerable restriction on the choice of chelator and may effectively exclude hexadentate ligands from consideration. Most siderophores, including desferrioxamine and hexadentate ligands, have molecular masses greater than 500 Da. In contrast, bidentate and tridentate ligands (Figure 2 ), by virtue of their much lower molecular masses, are predicted to possess higher absorption efficiencies. the extracellular or intracellular pools. Compounds with short plasma half-lives are thus likely to be less effective due to the limited pool of chelatable iron present within the body at any one time. Desferrioxamine possesses a very short plasma half-life, which is the reason for administration via an infusion pump [l 13.
Toxicity of ligands
T h e potential toxicity associated with metal ligands may originate from a number of factors, including inhibition of metalloenzymes, redox cycling of the metal complex, thereby generating free radicals, and the kinetic lability of the complex leading to metal redistribution.
Enzyme inhibition
In general, iron chelators do not directly inhibit haem-containing enzymes due to the inaccessibility of porphyrin-bound iron to chelating agents. In contrast many non-haem iron-containing enzymes such as the lipoxygenase and aromatic hydroxylase families and ribonucleotide reductase are susceptible to chelator-induced inhibition [ 121.
T h e aromatic amino acid hydroxylases are particularly susceptible to inhibition by bidentate aromatic ligands, for instance catechols and hydroxypyridinones, owing to the similar molecular characteristics of the inhibitor and the substrate. However, the introduction of a hydrophilic substitutent at the 2-position of hydroxypyridinones markedly reduces the inhibitory properties, presumably due to steric interference of the chelation process at the enzyme active site [13] . Thus by careful modification of physicoligand, chelators can be designed which exert minimal inhibitory influence on most critical metalloenzymes.
Chelator bioavailability and disposition
T h e metabolic Properties of Chelating agents Play chemical properties and molecular nature of the a critical role in determining both their efficacy and toxicity. It is important to ensure that the agent is not metabolically degraded to metabolites which lack the ability to bind iron. This will inevitably require the use of higher drug levels, increasing the risk of inducing toxicity. Chelators are likely to be more resistant to metabolism if their backbones lack ester and amide links and to a lesser extent hydroxamate links [lo] . T h e catechol function is a disadvantage with respect to metabolism as there are numerous enzymes specifically designed to modify the catechol entity, for instance catechol-0-methyl transferase.
Ideally for maximal chelation, a chelator must be present within the extracellular fluids at both a reasonable concentration (10-25 pM) and length of time to ensure interception of iron from either
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Redox activity
Chelators that bind both iron( 11) and iron( I I I) are capable of redox cycling. This is an undesirable property for iron-scavenging molecules, as such cycling can lead to the production of hydroxyl radicals. Significantly, the high selectivity of siderophores for iron(II1) over iron(I1) renders redox cycling under biological conditions quite improbable. In contrast, chelators which utilize nitrogen, as well as oxyanions, as ligands, possess lower redox potentials and the co-ordinated iron can be reduced enzymically under biological con-ditions. Some of these complexes redox cycle under aerobic conditions, thereby generating oxygen radicals.
Hydrophilicity
Although bidentate and tridentate ligands possess a clear advantage over hexadentate ligands with respect to oral bioavailability, their enhanced ability to permeate membranes renders them potentially more toxic. Thus the penetration of the blood-brain barrier is one of the likely side-effects associated with bidentate and tridentate ligands. Blood-brain barrier permeability is predicted to be low for most hexadentate compounds, by virtue of their higher molecular mass. With low-molecular-mass molecules ( < 300 Da), penetration is largely dependent on the lipophilicity; however, molecules with partition coefficients below 0.05 result in relatively poor penetration. T h u s chelators with partition coefficients lower than this critical value are predicted to show poor entry into the central nervous system. Brain penetration of 3-hydroxypyridin-4-ones is strongly dependent on their lipophilicity [14] .
Conclusions
Over the past 30 years many attempts have been directed at the design of non-toxic orally active chelators; for iron, only one clinically useful compound has emerged to date, deferiprone. Since 1995 a number of significant advances have been made and other more efficacious orally active chelators will soon join deferiprone. Several lead compounds have been identified and are under active development for the treatment of transfusional iron overload. T h e successful introduction of such compounds will impact considerably on the therapeutic outcome and quality of life for the thalassaemic population. There is a potential for iron chelation in a wide range of clinical situations. Once a chelator has been clinically proven in thalassaemic patients, such compounds will almost certainly find application for the treatment of other disease states, such as sickle cell anaemia [7] .
